Comparison of OVD and BSS for Maintaining the Anterior Chamber during IOL Implantation by Lee, Ho Young et al.
15
Korean J Ophthalmol 2011;25(1):15-21
DOI: 10.3341/kjo.2011.25.1.15 pISSN: 1011-8942 eISSN: 2092-9382
Original Article
Comparison of OVD and BSS for Maintaining the Anterior 
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Purpose: To compare surgical results between conventional intraocular lens (IOL) implantation using an ophthalmic 
viscosurgical device (OVD) and IOL implantation using a balanced salt solution (BSS) after irrigation/aspiration 
(I/A) of the lens cortex.
Methods: A randomized prospective study was conducted on 62 patients who underwent cataract surgery. 
Following completion of conventional I/A of the lens cortex, we divided patients into two groups according to 
whether or not BSS was used. In group A (n = 31), the anterior chamber and the capsular bag were completely fil-
led with an OVD before IOL implantation. On the other hand, in group B (n = 31), BSS was irrigated into the ante-
rior chamber through a previous side port during IOL implantation. Surgical results were compared between the 
two groups.
Results: In both groups, IOP peaked six hours after surgery. The occurrence of an IOP spike by postoperative day 
one was observed in six cases (6 / 31) in group A and in no cases (0 / 31) in group B, a difference that was stat-
istically significant (p = 0.024). The values of endothelial cell density, central corneal thickness, anterior cham-
ber inflammation, myopic shift, and posterior capsule opacification were not significantly different between the 
two groups. 
Conclusions: Compared with the use of OVD for IOL implantation, use of BSS during IOL implantation resulted in re-
ductions in postoperative IOP spike and OVD removal time. 
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device 
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Phacoemulsification (phaco) with the use of an ophthalmic 
viscosurgical device (OVD) is the preferred technique for 
use in modern cataract surgery. Surgical benefits of OVD in-
clude maintenance of the anterior chamber, protection of the 
corneal endothelium, and facilitation of intraocular lens im-
plantation [1-3]. However, the OVD may cause an increase 
in intraocular pressure (IOP) and inflammation in the imme-
diate postoperative period, which may result in further endo-
thelial cell loss [4-8]. Therefore, to prevent these complica-
tions, the OVD should be removed via thorough aspiration 
after intraocular lens (IOL) implantation; however, an OVD 
located in the ciliary sulcus or behind the IOL may not be 
able to be easily removed. To solve these problems, follow-
ing irrigation/aspiration (I/A) of the lens cortex, we im-
planted the IOL using balanced salt solution (BSS) instead of 
filling the anterior chamber and the capsular bag with an 
OVD. The aim of this study was to evaluate and compare 
clinical results between the OVD group (group A) and the 
BSS group (group B) during the postoperative period. 
Materials and Methods
A randomized prospective study was conducted in Eulji 
General Hospital between March 2009 and September 2009 
on 62 eyes of 62 patients with senile cataracts. Informed con-
sent was obtained from all patients, and the study was ap-
proved by the Institutional Review Board of Eulji Medical 
Center. All patients underwent a detailed preoperative oph-
thalmic examination. Inclusion criteria were between 40 and 
80 years and senile cataract greater than NO2 or NC2 accord-
ing to the Lens Opacities Classification System III classification. 
Exclusion criteria included cases with a small pupil, extremely Korean J Ophthalmol Vol.25, No.1, 2011
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Fig. 1. (A) Following irrigation/aspiration of the cortex, the anterior chamber is irrigated with balanced salt solution (BSS) 
through a side port using a 27-gauge Amvisc Plus needle before intraocular lens implantation. (B) Insertion of the intraocular lens 
into the capsular bag while the anterior chamber is maintained with BSS. 
shallow chamber, compromised endothelial cell function, cor-
neal disorder, complicated cataract, glaucoma, pseudoexfoli-
ation, severe myopia, and a previous history of laser-assisted 
in situ keratomileusis. Other intraoperative exclusion criteria 
were a total surgical time of more than 30 minutes and a total 
phaco time of more than 90 seconds. Patients who had a pos-
terior capsule rupture or those who were converted to an ex-
tracapsular cataract extraction during the procedure were ex-
cluded from subsequent analysis. Preoperative evaluation of 
patients included age, gender, and presence of any systemic 
diseases, such as hypertension or diabetes mellitus, best cor-
rected visual acuity (BCVA), and IOP estimated using a 
Goldmann’s applanation tonometer. Keratometry was per-
formed using a Canon RK-5 autorefractor keratometer 
(Canon, Tochigiken, Japan), while the axial length and the 
anterior chamber depth were measured using a Hi-Scan 
standard A-scan machine (Optikon 2000, Rome, Italy). The 
power of the IOL was calculated in all of the patients using 
the SRK-II formula. Selected patients were divided into two 
groups: group A (OVD-used group) and group B (BSS-used 
group). The BCVAs were converted to the logarithms of the 
minimum angle of resolution (logMAR).
Surgery was performed using a Stellaris (Bausch & Lomb, 
Rochester, NY, USA) phaco machine by a single surgeon. 
Under topical anesthesia using 4% lidocaine, a side port was 
created at 11 o’clock limbus for the right eye (5 o’clock in the 
left eye) using a no. 7513 blade. A clear corneal incision in 
the temporal limbus was made with a 2.8 mm microsurgical 
knife (Kai Industries Co., Seki, Japan). The anterior chamber 
was filled with OVD (Amvisc Plus), and then a continuous 
curvilinear capsulorrhexis measuring approximately 5.0 mm 
to 5.5 mm in diameter was created using a 30-gauge needle 
with a curved tip and a capsular forceps. Hydrodissection and 
hydrodelineation were performed to achieve free rotation of 
the nucleus. 
Following in-the-bag phaco of the nucleus using the di-
vide and conquer technique, the cortex was removed using 
I/A. In group A, the anterior chamber and the capsular bag 
were completely filled with Amvisc Plus, and the IOL was 
then implanted into the capsular bag. In group B, the ante-
rior chamber and the capsular bag were not filled with 
OVD; however, BSS was used for maintenance of the ante-
rior chamber shape. The surgeon evaluated the patency of a 
27-gauge Amvisc Plus needle connected to a three-way irri-
gation line with a 140 cm irrigation bottle height. After a 
small amount of OVD (about 0.05 mL) was placed on an 
IOL injector cartridge, the surgeon advanced the tip of the 
IOL injector into the anterior chamber through a temporal 
wound using his right hand. After a slight deepening of the 
anterior chamber by slight pressure from the injector, the 
surgeon inserted the 27-gauge Amvisc Plus needle into the 
anterior chamber through a side port, using the left hand for 
continuous irrigation with BSS, while maintaining irriga-
tion using the phaco machine foot switch (Fig. 1A and 1B). 
The IOL, a one-piece, foldable, hydrophilic acrylic, asphe-
ric Teklens II lens (Tekia Inc., Irvine, CA, USA), was then 
fully inserted into the capsular bag. Following IOL im-
plantation in both groups, the IOL was centered using the 
IOL rotator, and residual Amvisc Plus was removed as thor-
oughly as possible. In all cases, the corneal wound was hy-
drated at the conclusion of the surgery. Subconjunctival in-
jection consisting of 8 mg/0.2 mL triamcinolone acetonide 
was administered.
The IOP, endothelial cell density (ECD), central corneal 
thickness (CCT), anterior chamber inflammation, myopic 
shift, posterior capsule opacification (PCO), OVD removal 
time, and facilitation of IOL implantation were measured and 
compared between the two groups. Postoperative IOP was HY Lee, et al. BSS-Used IOL Implantation
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Fig. 2. The change in mean intraocular pressure (IOP) over time. In 
both groups, IOP peaked six hours after surgery, with a mean of 
21.43 ± 6.41 mmHg in group A and 17.41 ± 5.12 mmHg in group 
B. The difference between the two groups was significant (p =
0.034). IOP then showed a gradual decrease to preoperative levels 
by seven days postoperative.
Table 1. Clinical characteristics of the study subjects
Group A Group B p-value
Patient age (yr) 65.42 ± 12.20 63.23 ± 9.44 0.756
*
Cataract density (1-6 scale) 3.71 ± 0.46   3.52 ± 0.68 0.549
*
TPPV history   8 / 31     5 / 31 0.534
†
Diabetes mellitus frequency  17 / 31   19 / 31 0.797
†
NPDR 9 10
PDR 8  9
Hypertension frequency  10 / 31   10 / 31 1.000
†
BCVA (logMAR)   0.61 ± 0.42   0.52 ± 0.34 0.457
*
Preoperative mean IOP (mmHg) 14.42 ± 4.21 13.32 ± 5.18 0.662
*
Mean operation time (min) 17.28 ± 5.67 16.45 ± 7.42 0.557
*
TPPV = trans pars plana vitrectomy; NPDR = nonproliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; BCVA = best 
corrected visual acuity; logMAR = logarithms of the minimum angle of resolution; IOP = intraocular pressure.
*Mann-Whitney U-test; 
†Fisher's exact test.
measured using a Goldmann’s applanation tonometer at six 
hours, one day, one month, three months, and six months post 
operation. An IOP spike was defined as an increase greater 
than 30 mmHg by postoperative day one. Specular micro-
scopy using the Topcon SP-2000P (Topcon Co., Tokyo, Japan) 
was performed preoperatively and three months after surgery. 
CCT was measured via ultrasound pachymetry using a 
Pocket pachymeter (Quantel Medical Inc., Clermont-Ferrand, 
France) preoperatively, and one day, one week, and three 
months after surgery. For evaluation of postoperative in-
flammation, the numbers of anterior chamber cells were 
graded with a 2 mm long and 1 mm wide slit beam with max-
imal light intensity and magnification. The findings were re-
corded as grade 0 if there was less than one cell in the field; 
grade 1+ if there were between 2 and 15 cells; grade 2+ if 
there were between 16 and 25 cells; grade 3+ if there were 
between 26 and 50 cells; and grade 4+ if there were more 
than 50 cells. Refractive myopic shift was defined as a spher-
ical equivalent (SE) difference greater than -1.5 diopter compared 
to aiming SE at postoperative three months, as determined 
with a Canon RK-5 autorefractor keratometer. PCO was as-
sessed with the pupils dilated by one author who was blind-
ed to the surgical method used. Slitlamp photography of the 
IOL and posterior capsule were performed using 
retroillumination. PCO was defined as lens epithelial cell 
migration onto the visual axis with a BCVA reduction of 
more than two lines on the Snellen chart. Also, the time 
needed for complete removal of the OVD from the chamber 
using the I/A handpiece was measured. For removal of the 
OVD, the flow rate was fixed to 40 mL/min and the vacuum 
was set to 400 mmHg. The surgeon subjectively assessed 
facilitation of IOL implantation using a three point scale of 
1 = poor; 2 = average; 3 = good. All statistical analyses were 
performed using SPSS ver. 17.0 (SPSS Inc., Chicago, IL, 
USA). Randomization was performed preoperatively using 
a statistical random table. 
Results
Table 1 shows the baseline information of the patients 
who participated in this study. The mean age was 65.42 ± 12.20 
years in group A and 63.23 ± 9.44 years in group B, and the 
corresponding mean cataract densities were 3.71 ± 0.46 and 
3.52 ± 0.68. Preoperative mean IOP was 14.42 ± 4.21 
mmHg in group A and 13.32 ± 5.18 in group B, and the pre-
operative mean BCVA (logMAR) was 0.61 ± 0.42 in group 
A and 0.52 ± 0.34 in group B. No statistically significant 
differences in age, cataract density, preoperative IOP, or 
preoperative BCVA were observed between the two groups 
before surgery. 
Fig. 2 shows the change in IOP over time. In both groups, 
IOP peaked six hours after surgery, with a mean IOP of 21.43 
± 6.41 mmHg in group A and 17.41 ± 5.12 mmHg in group B. 
The difference was significant (p = 0.034, according to the 
Mann-Whitney U-test). The IOP then gradually decreased to Korean J Ophthalmol Vol.25, No.1, 2011
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Fig. 3. Assessment of the facilitation of intraocular lens implantation. 
In group A, the ratings ‘good’, ‘average’, and ‘poor’ were assigned in 
87% (27 / 31), 13% (4 / 31), and 0% (0 / 31) of cases, respectively, 
while those in group B were 74% (23 / 31), 26% (8 / 31), and 0% 
(0 / 31) (p = 0.202 according to the Mann-Whitney U-test). 
Table 2. Frequency of intraocular pressure spikes by post- 
operative day one
Group A Group B p-value
*
Intraocular pressure spikes 6 / 31 0 / 31 0.024
*Calculated using Fisher's exact test.
Table 3. Endothelial cell density (cells/mm
2)
Group A Group B p-value
*
Preoperative 2,432 2,361 0.918
Three months postoperative 2,357 2,284 0.828
Reduction rate 3.1% 3.3% 0.945
*Calculated using the Mann-Whitney U-test.
Table 4. Central corneal thickness (CCT, μm) in both groups
Group A Group B p-value
*
Preoperative CCT 521.28 ± 24.44 519.34 ± 18.75 0.754
Postoperative (increased rate)
1 day CCT  537.76 ± 31.38 (+3.16%) 529.41 ± 24.54 (+1.94%) 0.101
1 wk CCT  530.18 ± 22.57 (+1.71%) 524.12 ± 19.76 (+0.92%) 0.307
3 mon CCT 524.25 ± 36.11 (+0.57%) 520.15 ± 17.21 (+0.16%) 0.425
*Calculated using the Mann-Whitney U-test.
Fig. 4. Mean ophthalmic viscosurgical device removal time was 
50.42 ± 3.83 seconds in group A and 8.29 ± 4.40 seconds in 
group B, illustrating that the time to complete removal of Amvisc 
Plus was significantly less in group B (p ≤ 0.001 according to the 
Mann-Whitney U-test).
Table 5. Anterior chamber cells in both groups at the post- 
operative periods
Group A Group B p-value
*
Postoperative 
    1 day  3.3+ 3.2+ 0.841
    1 wk  1.6+ 1.4+ 0.744
    1 mon 0 0 0.425
*Calculated using the Mann-Whitney U-test.
preoperative levels by seven days postoperative. Six IOP 
spikes were observed in group A (6 / 31) one day after sur-
gery, although no cases (0 / 31) were observed in group B, 
another significant difference (p = 0.024) (Table 2). 
Table 3 shows ECD preoperative and three months 
postoperative. Reduction rates of ECD three months after 
surgery were 3.1% in group A and 3.3% in group B; this dif-
ference was not significant (p = 0.945). In group A, the mean 
postoperative BCVAs (logMAR) were 0.35 ± 0.42, 0.27 ± 0.31, 
and 0.25 ± 0.35 at one day, one month, and three months, 
respectively. In group B, the respective mean postoperative 
BCVAs (logMAR) were 0.33 ± 0.37, 0.24 ± 0.31, and 0.26 ± 
0.36. None of these differences were significant (p = 0.643, 
0.511, and 0.836, respectively, according to the Mann-Whitney 
U-test). 
Postoperative CCT changes in group A were +3.16%, 
+1.71%, and +0.57% at day one, one week, and three 
months, respectively. In group B, the postoperative CCT 
changes were +1.94%, +0.92%, and +0.16%, respectively. 
None of these CCT changes were significantly different (p = 
0.101, 0.307, and 0.425) (Table 4). At one day, one week, and 
one month postoperative, the mean numbers anterior cham-
ber cells in group A were 3.3+, 1.6+, and 0 and were 3.2+, 
1.4+, and 0 in group B, respectively. None of these anterior 
chamber cell numbers were significantly different (p = 0.841, HY Lee, et al. BSS-Used IOL Implantation
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Table 6. Frequencies of myopic shift and posterior capsule opacification
Group A Group B p-value
*
Myopic shift (more than -1.5 diopter) 4 / 31 0 / 31 0.113
Posterior capsule opacification 3 / 31 0 / 31 0.238
*Calculated using Fisher's exact test.
Table 7. Comparison of intraocular pressure spike frequencies by postoperative day one between ‘vitrectomized eyes’
and ‘not vitrectomized eyes’
Vitrectomized eyes No vitrectomized eyes p-value
*
Group A  50% (4 / 8) 8.7% (2 / 23) 0.026
*Calculated using Fisher’s exact test.
0.744, and 0.425) (Table 5). 
Three months post operation, there were four refractive 
myopic shifts (4 / 31) of more than -1.5 diopter in group A, 
while no refractive myopic shift (0 / 31) occurred in group 
B (p = 0.113). Six months postoperative, PCO occurred in 
three cases (3 / 31) in group A and in no case (0 / 31) in group 
B (p = 0.238) (Table 6). Fig. 3 shows the assessment of fa-
cilitation of IOL implantation. In group A, ‘good’, ‘average’, 
and ‘poor’ ratings were assigned to 87% (27 / 31), 13% (4 /
31), and 0% (0 / 31) of the eyes, respectively. In group B, 
these proportions were 74% (23 / 31), 26% (8 / 31), and 0% 
(0 / 31), respectively (p = 0.202). We measured the removal 
times for Amvisc Plus in group A and group B and calcu-
lated a mean OVD removal time of 50.42 ± 3.83 seconds in 
group A and that of 8.29 ± 4.40 seconds in group B (Fig. 4). 
Significantly less time was required for complete removal 
of Amvisc Plus in group B compared to that in group A (p ≤ 
0.001). 
Discussion
Viscoelastic materials can be characterized according to 
their chemical composition (e.g., sodium hyaluronate, chon-
droitin sulfate, hydroxypropyl methylcellulose), physical 
properties (e.g., molecular weight, viscosity, cohesive versus 
dispersive), or both. One of the various OVDs, Amvisc Plus, 
which was used in this study, is a highly viscous, 132,000 cP, 
cohesive viscoelastic agent containing 1.6% high molecular 
weight sodium hyaluronate. Due to lubrication and trans-
parency, this OVD facilitates IOL implantation through the 
maintenance of anterior chamber depth and visibility, mini-
mizing interactions between tissues. However, because the 
postoperative IOP may increase due to residual Amvisc Plus, 
complete removal from the anterior chamber and the capsu-
lar bag should be assured at the conclusion of surgery to pre-
vent or minimize post-operative IOP increase.
The viscoelastic substance remaining in the eye may cause 
mechanical obstruction of the trabecular meshwork and is a 
major reason for early postoperative IOP increase [9]. In 
1983, Berson et al.  [9] reported that sodium hyaluronate 
caused a substantial decrease (55% to 60%) in the outflow of 
aqueous humor when injected into the anterior chamber. 
Subsequently, it has become well accepted that retained vis-
coelastic materials inhibit aqueous outflow and result in in-
creased IOP. Arshinoff [10] has published multiple studies 
comparing different viscoelastic materials and concluded 
that, if not completely removed, all types of OVD will cause 
postoperative increases in IOP. Koçak-Altintas et al. [11] al-
so reported a higher incidence of postoperative IOP increase 
associated with use of higher viscosity OVD. 
Thorough removal of viscoelastic substances is vital for 
avoidance of a postoperative IOP increase. However, com-
plete removal of the OVD behind the IOL is known to be 
difficult. Several surgical techniques for removal of viscoe-
lastic substances, particularly from behind the IOL, have 
been described [12-14]; however, complete avoidance of a 
postoperative IOP increase has not been achieved with any 
technique. 
Nayak and Jain [15] reported that continuous anterior 
chamber infusion using an anterior chamber maintainer and 
omission of OVD during phaco and IOL implantation did not 
cause a significant difference in corneal swelling or endothe-
lial cell loss in the immediate postoperative period up to one 
month.  
In our study, we used OVD for facilitation of continuous 
curvilinear capsulorrhexis and protection of the endothelium. 
Following removal of the lens nucleus via phaco and I/A of 
the cortex, we implanted the IOL using only BSS through a 
previous side port. As a result, we expected to reduce the risk 
for high postoperative IOP due to residual OVD. A lower 
mean IOP six hours after surgery, as well as the lower fre-
quency of IOP spike by postoperative day one, indicates that 
our method did reduce the risk for elevated postoperative 
IOP. 
Our results suggest that the proposed method will be more 
useful in vitrectomized eyes with cataracts, a situation known 
to involve higher risks and complications compared to those 
in nonvitrectomized eyes. Challenges to removal of OVD be-
hind the IOL in vitrectomized eyes include greater fluctua-
tion of the anterior chamber, intraoperative miosis, an ex-
cessively mobile posterior capsule  [16] due to weakened 
zonules, and loss of vitreous support [17]. In group A, four of Korean J Ophthalmol Vol.25, No.1, 2011
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eight eyes (50.0%) that had undergone previous vitrectomy 
experienced an IOP spike by postoperative day one, while 
IOP spike occurred in two of 23 eyes (8.7%) that had not un-
dergone vitrectomy (p = 0.026) (Table 7). 
Complete IOL fixation on the posterior capsule is another 
advantage of our method. Enhancement of the IOL optic 
barrier effect is one of the goals of in-the-bag fixation. If ac-
curately implanted into the capsular bag, the lens forms a 
barrier to central migration of lens epithelial cells by near 
complete contact of the IOL optic to the posterior capsule so 
that cells rarely reach the center of the posterior capsu-
le [18]. However, the IOL can be positioned more anterior 
to the aiming location if there is residual OVD behind the 
IOL. This creates potential space between the posterior sur-
face of the IOL and the posterior capsule and induces great-
er PCO. Here, we identified four patients with a myopic 
shift of greater than -1.5 diopter, although the myopic shift 
was not significant (p = 0.113). Within six months post op-
eration, PCO had occurred in three of these patients (3 / 4). 
Because the proposed methodology only utilizes approx-
imately 0.05 mL of OVD for IOL loading in the injector car-
tridge, which is inserted into only the anterior chamber, the 
residual OVD was easily and completely removed using 
I/A. Thus, compared to conventional cataract surgery, not 
only was there significantly less time required for the over-
all procedure but removal of OVD in the anterior chamber 
was simplified.  
There are several drawbacks to our methodology. First, 
when the IOL is inserted into the anterior chamber, the sur-
geon must hold the IOL injector with his right hand, while 
simultaneously irrigating the needle with his left hand. 
Improper performance of the procedure may lead to compli-
cations, such as sulcus implantation or corneal wrinkling. 
Although we initially experienced inappropriate insertion 
in two cases (2 / 31), it was corrected immediately using an 
IOL rotator. After correction, we did not notice a difference 
with regard to facilitation of IOL implantation between the 
two groups. Second, because the 27-gauge Amvisc Plus 
needle has a small diameter (about 0.3 mm), its flow rate 
(about 1.5 mL/min) is not sufficient to produce a full ante-
rior chamber depth, even though the maximal bottle height 
was 140 cm. However, in spite of this condition, we did not 
experience posterior capsule rupture or zonular dialysis, 
and IOL implantation into the capsular bag was successful 
in all cases. Third, although we only used high viscosity co-
hesive Amvisc Plus in this study, other OVDs may yield dif-
ferent results. Further and larger studies using the same 
method with other OVDs are required. Lastly, we could not 
guarantee that the OVD was completely removed from the 
anterior chamber because of its lack of visibility.
The safety of cataract surgery has improved markedly with 
advancements in surgical techniques, equipment, and OVDs. 
However, OVD-related complications, such as IOP spikes 
and inflammation, may occur. Following I/A, our method 
uses irrigating solution and a 27-gauge Amvisc Plus needle 
instead of additional OVD. In conclusion, our technique can 
reduce the risk for postoperative high IOP due to residual 
OVD, especially in vitrectomized eyes, as well as the un-
wanted surgical costs incurred by additional OVD. Thus, 
BSS-based IOL implantation may be an alternative new 
method to replace OVD-based IOL implantation.
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